Molecular pathogenesis and a consequent classification of multiple myeloma.
about
Deficient spindle assembly checkpoint in multiple myelomaAdvances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myelomaInitial genome sequencing and analysis of multiple myelomaTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsCyclin D as a therapeutic target in cancerEvaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaDLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathwayRegistered report: BET bromodomain inhibition as a therapeutic strategy to target c-MycMaintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.Proteomics and biomarkers in clinical trials for drug developmentFunctional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasmsGenomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survivalA Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaCombination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19bMolecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myelomaMicroRNA: important player in the pathobiology of multiple myelomaCyclin K and cyclin D1b are oncogenic in myeloma cells.In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.MMSET: role and therapeutic opportunities in multiple myeloma.Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significanceTranscriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.Proteomic analysis of gossypol induces necrosis in multiple myeloma cells.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.Detection of serum tumor markers in multiple myeloma using the CLINPROT system.Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Man with Fragile X-associated Tremor/Ataxia Syndrome.Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression.
P2860
Q21560908-A6A05ADB-C2B9-42AF-8299-E2596EFDDE52Q24619589-B9BF5B81-4151-49DF-9D4C-A4289AD5FD0BQ24629117-5D4E5E39-1854-4350-B797-4AF0C5A3A10CQ26827580-01B21D1C-4E89-4085-88BB-DC01AB14A52FQ28242623-E18F090B-BF33-4540-87FC-BDCFD98A171EQ28296718-C3F61111-6909-4F73-900C-972F2C26EE74Q28392462-814F83B8-3190-424F-B722-A1628B538D8AQ28647939-A5A6CBCC-2384-4568-B164-709EDC3A1B1DQ30275382-7FA59766-2116-4101-B5A4-133B15A927B7Q30370141-3C1C0FEF-DCFC-4057-8210-3DFB0877A284Q30402667-3C034B5A-F014-4784-A6CE-956020F9C450Q30490975-E9F07C52-6F74-4D12-A233-D1B8D0E6CE0DQ30498959-94E44C7F-6B2C-452A-BD43-1003E4570042Q31077729-F5106A1B-9F83-4FA5-96DA-88C6A69FA53AQ33367792-96A8FC48-66DD-4C97-B886-8B2350176B0EQ33426534-9DF6CF24-7A98-4EA8-9F91-563875F5B935Q33627051-EEBC4FD6-9C22-4FD6-BA94-BBF6330E6908Q33632244-7B474CF0-1557-4267-830B-DC130E3A69A0Q33702365-5A1B7B7E-C718-4ECF-BB74-4B0601D4D636Q33709470-ED0907E2-5531-421A-9111-51DD126BC74CQ33786861-F6AE3096-82CB-4D93-B4CC-CC88B0998643Q33895292-38AB9FA3-1DDF-428B-B8E2-410FCC320377Q33902726-806D04CB-E8EE-4CF1-913E-7DF28A7078CCQ33908640-D00350C1-1F9E-47B2-9BE7-E0A89D3F011AQ33948015-68CBFDC5-AD40-433F-885F-BDF7FFB2F5AAQ33952861-7BA5E1E7-73EB-40E1-9F07-41671E0A0551Q33978937-54AF3019-594C-4F4A-9D23-9C67F157DADAQ34020965-1DD2D02E-CB72-4255-813E-A7EBCD560397Q34025829-CCDEC25A-49E7-43C6-85CC-AB92D9C68853Q34093292-4A95DF68-DC20-4719-8488-9FBE085557FBQ34114032-B2B2B886-1088-4958-B648-53332DB97B0FQ34134986-63AF4A11-73E2-4717-92BA-57843325BB12Q34223730-3A819DE0-7F2E-4351-89D4-A9271134FED0Q34249148-91F95352-795D-4E77-9B53-393C1590EA4EQ34345502-236FAFCB-2365-4FC1-85BF-3D1F0F2B21ADQ34431310-45117569-BA29-4687-AD53-CD2647F825DDQ34449324-44C6C02F-BA3A-4BC9-80DB-FF1BBDA8E22BQ34451553-F3B526A3-1BD6-4437-B3DC-8830BC2A37B9Q34460989-28E50CEC-1A25-4099-9AA4-F163099F373DQ34517905-90571A96-CEC0-4BB8-ADB6-502770724242
P2860
Molecular pathogenesis and a consequent classification of multiple myeloma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Molecular pathogenesis and a consequent classification of multiple myeloma.
@ast
Molecular pathogenesis and a consequent classification of multiple myeloma.
@en
type
label
Molecular pathogenesis and a consequent classification of multiple myeloma.
@ast
Molecular pathogenesis and a consequent classification of multiple myeloma.
@en
prefLabel
Molecular pathogenesis and a consequent classification of multiple myeloma.
@ast
Molecular pathogenesis and a consequent classification of multiple myeloma.
@en
P356
P1476
Molecular pathogenesis and a consequent classification of multiple myeloma.
@en
P2093
P Leif Bergsagel
W Michael Kuehl
P304
P356
10.1200/JCO.2005.05.021
P407
P577
2005-09-01T00:00:00Z